Gene editing

CRISPR-ready neurons
#bit bio #CRISPR #Gene editing #Genetics / genomics #Neurology #Neuroscience

New CRISPR-ready neurons could democratise genomics

bit.bio has launched the first offering from its new product range ioCRISPR-Ready Cells, which allow research and drug discovery scientists to knockout any gene of interest in glutamatergic neurons. CRISPR-Ready ioGlutamatergic Neurons are first-in-class stem-cell derived human neurons containing a constitutively-expressed Cas9 nuclease for gene knockouts… Read More

#News

CRISPR gene editing
#CRISPR #CRISPR-Cas9 #Gene editing #Lithuania #Turning Science into Business

Turning Science into Business: Commercialising CRISPR

While attending Life Science Baltics 2023, Diana Spencer spoke to Monika Paule, CEO and Co-founder of Caszyme, about creating a company based on CRISPR gene editing and some of the challenges of operating in this dynamic area of research. DS: What was the motivation for launching Caszyme and what challenges did… Read More

#Exclusive Content

#AAV #AskBio #Duchenne muscular dystrophy #Gene editing #Giant axonal neuropathy #Haemophilia #Pompe disease

Podcast: The evolution and future of gene therapy

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr… Read More

#News

CRISPR gene editing
#Aldevron #Cell and gene therapy #CRISPR #Gene editing #Integrated DNA Technologies #Partnership

Partners working to realise the future of genomic medicine

CRISPR gene editing companies Integrated DNA Technologies (IDT) and Aldevron have inked a new global distribution agreement to expand CRISPR products for cell and gene therapy customers. IDT will stock and sell three additional research use only (RUO) and current good manufacturing practice (cGMP) CRISPR nucleases… Read More

#News

CRISPR gene editing
#Cancer research #CAR-T #CRISPR #CRISPR-Cas9 #Gene editing #Oncology

CRISPR breakthroughs: New solutions for common diseases

Listen to this article on the DDW Podcast: Rolf Turk, Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Since its discovery in 2012, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionised the biomedicine and cell and gene therapy fields,… Read More

#Cancer Research #Exclusive Content

Genomics
#Drug discovery #Gene editing #Genetics / genomics #Genome editing #The Jackson Laboratory #Transcriptomics

eBook: The impact of genomics on drug discovery

The latest eBook by DDW ‘The impact of genomics on drug discovery: Creating new opportunities’ is out now. This 24-page eBook sponsored by The Jackson Laboratory looks at the key use-cases for genomics and how it is improving drug discovery and development projects. Download this exclusive eBook to learn… Read More

#News

#Drug discovery #Gene editing #Genetics / genomics #Genome editing #The Jackson Laboratory #Transcriptomics

The impact of genomics on drug discovery: Creating new opportunities

This 24-page eBook sponsored by The Jackson Laboratory looks at the key use-cases for genomics and how it is improving drug discovery and development projects. Download this exclusive eBook to learn more about: If animal genomics can help find therapies for human disease Key challenges and drivers of the genomics market How… Read More

#DDW eBooks #Intelligence

ioDisease Model Cells
#bit bio #Cell coding #CRISPR-Cas9 #Gene editing

bit.bio launches custom disease model cells

Cell coding company bit.bio has launched a new disease model cell offering enabling scientists to commission disease-relevant mutation of interest.   The company’s new Custom ioDisease Model Cells offering lets scientists choose the disease-relevant mutation they’re interested in. The disease-relevant mutation is engineered into bit.bio’s human ioWild Type … Read More

#News

CAR-T therapy
#Cancer research #CAR-T #Cell therapy #CRISPR #CRISPR-Cas9 #Gene editing #Oncology #Solid tumours

Double knockout strategy could boost CAR-T in solid tumours

A new approach that delivers a ‘one-two punch’ to help T cells attack solid tumours is the focus of a preclinical study by researchers from the Perelman School of Medicine at the University of Pennsylvania. The findings showed that targeting two regulators that control gene functions… Read More

#Cancer Research #News #Trending News

CRISPR gene editing
#CRISPR #Gene editing #Genetics / genomics #Stem cells

New research begins to write the rules on CRISPR activation

UK researchers, from the Wellcome Sanger Institute and collaborators, have used human stem cells and neurons to investigate what features influence how well CRISPR activation works for different sets of genes. Published in Molecular Cell, the study explains the rules determining to what extent genes respond… Read More

#News

#3D modelling #Biochemistry #CRISPR #DNA #Drug discovery #Gene editing #Genomics #Mass spectrometry / NMR #Screening

Podcast: Mass spectrometry and CRISPR

This is the latest episode of the free DDW podcast, “Mass spectrometry and CRISPR are pillars of drug discovery”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “How ASMS offers more than seeing what sticks” and “… Read More

#News

#Clinical trial #CRISPR #FDA #Gene editing #Gene therapy #In vivo #Intellia Therapeutics

FDA clears in vivo gene editing therapy for trials in US

The US Food and Drug Administration (FDA) has cleared Intellia Therapeutics’ Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).  Intellia is a clinical-stage genome editing company focused on developing potentially curative therapies using CRISPR-based technologies.   The decision will enable the company to include the… Read More

#News #Regulatory #Trending News

Genetic engineering
#Cell and gene therapy #CNS #Gene editing #Gene therapy #Genetics / genomics #Paediatrics #Stem cells

Gene therapy for ‘childhood dementia’ shows promise

An investigational gene therapy for Sanfilippo syndrome – which leads to a form of childhood dementia – has shown promising early results in a proof-of-concept study.  The study found that four out of five patients diagnosed with Sanfilippo have continued to gain cognitive skills in line with… Read More

#Editor's Choice #News

Organoids
#Drug development #Drug discovery #Drug screening #Gene editing #In vitro #In vivo #Organoids #Personalised medicine

Gene editing in organoids: accounting for complexity in drug discovery

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening.  The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s… Read More

#Exclusive Content

Cancer cells
#Brain disease #Cancer research #Cell and gene therapy #CRISPR #CRISPR-Cas9 #Gene editing #Mouse models #Neuroscience #Oncology

Scientists turn cancer cells into anticancer agents

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity.   In this early research, Khalid Shah, Professor of Neurosurgery at Harvard Medical School and Brigham and Women’s Hospital, and colleagues tested the vaccine in an advanced mouse model of brain… Read More

#Cancer Research #News #Trending News